{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["97(11)"],"submitter":["Vantyghem MC"],"pubmed_abstract":["<h4>Context</h4>For the last 10 yr, continuous glucose monitoring (CGM) has brought up new insights into the accuracy of blood glucose analysis.<h4>Objective</h4>Our objective was to determine how islet graft function was able to influence the various components of dysglycemia after islet transplantation (IT).<h4>Design and setting</h4>We conducted a single-arm open-labeled study with a 3-yr follow-up in a referral center (ClinicalTrial.gov identifiers NCT00446264 and NCT01123187).<h4>Patients</h4>Twenty-three consecutive patients with type 1 diabetes (14 islet alone, nine islet after kidney) received IT within 3 months using the Edmonton protocol.<h4>Intervention</h4>INTERVENTION included 72-h CGM before and 3, 6, 9, 12, 24, and 36 months after transplantation.<h4>Main outcome measure</h4"],"journal":["The Journal of clinical endocrinology and metabolism"],"pagination":["E2078-83"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3485599"],"repository":["biostudies-literature"],"pubmed_title":["Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3)."],"pmcid":["PMC3485599"],"pubmed_authors":["Defrance F","Kerr-Conte J","Raverdy V","Caiazzo R","Gmyr V","Hazzan M","Vantyghem MC","Balavoine AS","Arnalsteen L","Noel C","Pattou F"],"additional_accession":[]},"is_claimable":false,"name":"Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3).","description":"<h4>Context</h4>For the last 10 yr, continuous glucose monitoring (CGM) has brought up new insights into the accuracy of blood glucose analysis.<h4>Objective</h4>Our objective was to determine how islet graft function was able to influence the various components of dysglycemia after islet transplantation (IT).<h4>Design and setting</h4>We conducted a single-arm open-labeled study with a 3-yr follow-up in a referral center (ClinicalTrial.gov identifiers NCT00446264 and NCT01123187).<h4>Patients</h4>Twenty-three consecutive patients with type 1 diabetes (14 islet alone, nine islet after kidney) received IT within 3 months using the Edmonton protocol.<h4>Intervention</h4>INTERVENTION included 72-h CGM before and 3, 6, 9, 12, 24, and 36 months after transplantation.<h4>Main outcome measure</h4","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Nov","modification":"2025-06-01T00:11:17.836Z","creation":"2025-06-01T00:11:17.836Z"},"accession":"S-EPMC3485599","cross_references":{"pubmed":["22996144"],"doi":["10.1210/jc.2012-2115"]}}